cangrelor tetrasodium Inhibitor

Name: cangrelor tetrasodium Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5758198
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5758198

Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

cangrelor tetrasodium, Inhibitor

Full Product Name

cangrelor tetrasodium

Form/Format

Solid. Powder

Purity/Purification

100.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

864.29

Solubility

<1mg/ml refers to the product slightly soluble or insoluble

Formula

C17H21Cl2F3N5Na4O12P3S2

SMILES

[Na+].[Na+].[Na+].[Na+].CSCCNc1nc(SCCC(F)(F)F)nc2n(cnc12)[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)C(Cl)(Cl)P([O-])([O-])=O)[C@@H](O)[C@H]1O

CAS Number

163706-36-3

Target & IC50

GPR17

In Vitro

cangrelor, a non-sepesific GPR17 antagonist, alleviates pulmonary fibrosis partly by inhibiting macrophage inflammation in mice.Cangrelor is also a well-known anti-platelet agent. cangrelor (10mg/kg) not only significantly decreased BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreased the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice. In addition, cangrelor decreased the number of CD40 and MPO double positive neutrophils and the expression level of CD40 in BLM-treated mouse lungs[1].

Product Categories/Family for cangrelor tetrasodium, inhibitor

Endocrinology/Hormones; GPR; GPCR/G Protein

Product References and Citations for cangrelor tetrasodium, inhibitor

Tianwei Zhan, Taofeng Wei.Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice.Mol Immunol. 2020 Apr;120:83-92.
Tianwei Zhan, Taofeng Wei.Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice.Mol Immunol. 2020 Apr;120:83-92.
K. Beko, B. Kovanyi, F. Goloncser, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain[J]. Journal of Thrombosis and Haemostasis, 2017.
K. Beko, B. Kovanyi, F. Goloncser, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain[J]. Journal of Thrombosis and Haemostasis, 2017.
Bhattad VB, et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7(17):408.
Bhattad VB, et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7(17):408.

Other Notes

Small volumes of cangrelor tetrasodium, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for cangrelor tetrasodium purchase

MBS5758198 is an inhibitor targeting cangrelor tetrasodium.